In a U-turn, FDA orders AdComm for Sarepta’s DMD gene therapy

U-turn, FDA orders AdComm for Sarepta’s DMD gene therapyFierceBiotech
Sarepta crashes into an unexpected hurdle for its gene therapyInvestor’s Business Daily
Sarepta comes across doubts about drug approval. Buy the stock, analysts say.Barrons
Sarepta slips as FDA U-turn on panel muddies path to gene therapy approvalReuters
FAIRNESS ALERT: ROSEN, A TOP-TIER LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors Should Aware of Securities Class Action Investigation – SRPTbusiness thread
See full coverage on Google News

In a U-turn, FDA orders AdComm for Sarepta’s DMD gene therapy – FierceBiotech